TY - JOUR
T1 - Corticotropin-releasing hormone and dopamine release in healthy individuals
AU - Payer, Doris
AU - Williams, Belinda
AU - Mansouri, Esmaeil
AU - Stevanovski, Suzanna
AU - Nakajima, Shinichiro
AU - Le Foll, Bernard
AU - Kish, Stephen
AU - Houle, Sylvain
AU - Mizrahi, Romina
AU - George, Susan R.
AU - George, Tony P.
AU - Boileau, Isabelle
N1 - Publisher Copyright:
© 2016
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Corticotropin-releasing hormone (CRH) is a key component of the neuroendocrine response to stress. In animal models, CRH has been shown to modulate dopamine release, and this interaction is believed to contribute to stress-induced relapse in neuropsychiatric disorders. Here we investigated whether CRH administration induces dopamine release in humans, using positron emission tomography (PET). Eight healthy volunteers (5 female, 22–48 years old) completed two PET scans with the dopamine D2/3 receptor radioligand [11C]-(+)-PHNO: once after saline injection, and once after injection of corticorelin (synthetic human CRH). We also assessed subjective reports and measured plasma levels of endocrine hormones (adrenocorticotropic hormone and cortisol). Relative to saline, corticorelin administration decreased binding of the D2/3 PET probe [11C]-(+)-PHNO, suggesting dopamine release. Endocrine stress markers were also elevated, in line with activation of the hypothalamic-pituitary-adrenal axis, but we detected no changes in subjective ratings. Preliminary results from this proof-of-concept study suggests that CRH challenge in combination with [11C]-(+)-PHNO PET may serve as an assay of dopamine release, presenting a potential platform for evaluating CRH/dopamine interactions in neuropsychiatric disorders and CRH antagonists as potential treatment avenues.
AB - Corticotropin-releasing hormone (CRH) is a key component of the neuroendocrine response to stress. In animal models, CRH has been shown to modulate dopamine release, and this interaction is believed to contribute to stress-induced relapse in neuropsychiatric disorders. Here we investigated whether CRH administration induces dopamine release in humans, using positron emission tomography (PET). Eight healthy volunteers (5 female, 22–48 years old) completed two PET scans with the dopamine D2/3 receptor radioligand [11C]-(+)-PHNO: once after saline injection, and once after injection of corticorelin (synthetic human CRH). We also assessed subjective reports and measured plasma levels of endocrine hormones (adrenocorticotropic hormone and cortisol). Relative to saline, corticorelin administration decreased binding of the D2/3 PET probe [11C]-(+)-PHNO, suggesting dopamine release. Endocrine stress markers were also elevated, in line with activation of the hypothalamic-pituitary-adrenal axis, but we detected no changes in subjective ratings. Preliminary results from this proof-of-concept study suggests that CRH challenge in combination with [11C]-(+)-PHNO PET may serve as an assay of dopamine release, presenting a potential platform for evaluating CRH/dopamine interactions in neuropsychiatric disorders and CRH antagonists as potential treatment avenues.
KW - Addiction
KW - Corticotropin-releasing hormone (CRH)
KW - Dopamine (DA)
KW - Positron emission tomography (PET)
KW - Stress-induced relapse
KW - [C]-(+)-PHNO
UR - http://www.scopus.com/inward/record.url?scp=85002659079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85002659079&partnerID=8YFLogxK
U2 - 10.1016/j.psyneuen.2016.11.034
DO - 10.1016/j.psyneuen.2016.11.034
M3 - Article
C2 - 27951520
AN - SCOPUS:85002659079
SN - 0306-4530
VL - 76
SP - 192
EP - 196
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
ER -